---
search:
  boost: 2 
---

# Antihistamines & Mast Cell Stabilizers

This is a subcategory of Ophthalmic Agents.

## Decision Trees

- [Antihistamines & Mast Cell Stabilizers- Non-Preferred - Alocril, Alomide, Bepotastine*, Epinastine, Zerviate](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?origin=OfficeDotCom&lang=en-US&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUODFHRkdIM1VVVVZIOTJLS0hYWE5UNk9USyQlQCN0PWcu&topview=Preview)

## Formulary

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
| :--------------------- | :----------- | :------: | :---------: |
| Azelastine             |              |          |             |
| Bepreve <sup>BvG</sup> |              |          |             |
| Cromolyn               |              |          |             |
| Ketotifen              |              |          |             |
| Olopatadine            |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Alocril       |              |          |             |
| Alomide       |              |          |             |
| Epinastine    |              |          |             |
| Zerviate      |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=86)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=28)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
